Sodium benzoate, a D‐amino acid oxidase inhibitor, improved short‐term memory in patients with mild cognitive impairment in a randomized, double‐blind, placebo‐controlled clinical trial

Documents similaires

• Increase in luteinizing hormone is linked to reduction in depression in patients with dementia: Secondary analysis of a randomized clinical trial of benzoate
  par: Chieh‐Hsin Lin, et autres
  Publié: (2025)
• Trick or treat? It's time to rethink the role of placebo in clinical trial
  par: Ping‐Tao Tseng, et autres
  Publié: (2024)
• A double‐blind trial of decoded neurofeedback intervention for specific phobias
  par: Cody A. Cushing, et autres
  Publié: (2024)
• Association of impaired olfactory identification with prevalent mild cognitive impairment and regional brain atrophy: the Hisayama Study
  par: Toshifumi Minohara, et autres
  Publié: (2025)
• A randomized, double‐blinded, placebo‐controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder
  par: Tempei Otsubo, et autres
  Publié: (2025)